

Ref. No: 0914  
Date: 03/05/24  
Subject: Treatments (Rheumatology)

## REQUEST

1. Could you please provide the numbers of patients treated by the Rheumatology Department (for any condition) in the last 3 months with the following drugs:

- Abatacept [Orencia]
- Adalimumab [Humira]
- Adalimumab Biosimilars
- Apremilast [Otezla]
- Baricitinib [Olumiant]
- Bimekizumab [Bimzelx]
- Certolizumab [Cimzia]
- Etanercept [Enbrel]
- Etanercept Biosimilars
- Filgotinib [Jyseleca]
- Golimumab [Simponi]
- Guselkumab [Tremfya]
- Infliximab [Remicade]
- Infliximab Biosimilars
- Ixekizumab [Taltz]
- Risankizumab [Skyrizi]
- Rituximab [MabThera]
- Rituximab Biosimilars
- Sarilumab [Kevzara]
- Secukinumab [Cosentyx]
- Tocilizumab [Ro Actemra]
- Tocilizumab Biosimilars
- Tofacitinib [Xeljanz]
- Upadacitinib [Rinvoq]
- Ustekinumab [Stelara]

2. Could you please provide the numbers of patients treated for Psoriatic Arthritis ONLY in the last 3 months with the following drugs:

- Abatacept [Orencia]
- Adalimumab [Humira]
- Adalimumab Biosimilars
- Apremilast [Otezla]
- Bimekizumab [Bimzelx]
- Certolizumab [Cimzia]
- Etanercept [Enbrel]
- Etanercept Biosimilars
- Golimumab [Simponi]
- Guselkumab [Tremfya]
- Infliximab [Remicade]
- Infliximab Biosimilars
- Ixekizumab [Taltz]
- Risankizumab [Skyrizi]
- Secukinumab [Cosentyx]
- Tofacitinib [Xeljanz]
- Upadacitinib [Rinvoq]
- Ustekinumab [Stelara]

## RESPONSE

St Helens and Knowsley Teaching Hospitals NHS Trust and Southport and Ormskirk Hospital NHS Trust became a single legal entity known as Mersey and West Lancashire Teaching Hospitals NHS Trust on 1<sup>st</sup> July 2023, as such parts of the response may be provided in two sections relating to the hospital sites of each of the legacy organisations.

1. **Could you please provide the numbers of patients treated by the Rheumatology Department (for any condition) in the last 3 months with the following drugs:**

Treatment	No. Patients
Abatacept [Orencia]	92
Adalimumab [Humira]	10
Adalimumab Biosimilars	160
Apremilast [Otezla]	<5
Baricitinib [Olumiant]	82
Bimekizumab [Bimzelx]	0
Certolizumab [Cimzia]	34
Etanercept [Enbrel]	41
Etanercept Biosimilars	225
Filgotinib [Jyseleca]	19
Golimumab [Simponi]	51
Guselkumab [Tremfya]	<5
Infliximab [Remicade]	<5
Infliximab Biosimilars	56
Ixekizumab [Taltz]	6
Risankizumab [Skyrizi]	0
Rituximab [MabThera]	<5
Rituximab Biosimilars	39
Sarilumab [Kevzara]	<5
Secukinumab [Cosentyx]	65
Tocilizumab [Ro Actemra]	21
Tocilizumab Biosimilars	26
Tofacitinib [Xeljanz]	29
Upadacitinib [Rinvoq]	21
Ustekinumab [Stelara]	9

### Section 40: personal information

We are unable to provide precise figures when those figures refer to individuals in volumes of 5 or less due to the risk that individuals will be re-identified, as we are required to protect their identity under the General Data Protection Regulations & Data Protection Act 2018. In such circumstances Section 40(2) and Section 40(3) of the Freedom of Information Act apply. In this case, our view is that disclosure would breach the first data protection principle which states that personal data should be processed “lawfully, fairly and in a transparent manner”. It is the

lawful aspect of this principle which, in our view, would be breached by disclosure, and in such circumstances, Section 40 confers an absolute exemption on disclosure.

**2. Could you please provide the numbers of patients treated for Psoriatic Arthritis ONLY in the last 3 months with the following drugs:**

St Helens and Knowsley:

Pharmacy does not record the indication.

Southport and Ormskirk:

<b>Treatment</b>	<b>No. Patients</b>
Abatacept [Orencia]	0
Adalimumab [Humira]	<5
Adalimumab Biosimilars	47
Apremilast [Otezla]	<5
Bimekizumab [Bimzelx]	0
Certolizumab [Cimzia]	<5
Etanercept [Enbrel]	<5
Etanercept Biosimilars	27
Golimumab [Simponi]	<5
Guselkumab [Tremfya]	<5
Infliximab [Remicade]	0
Infliximab Biosimilars	6
Ixekizumab [Taltz]	<5
Risankizumab [Skyrizi]	0
Secukinumab [Cosentyx]	22
Tofacitinib [Xeljanz]	<5
Upadacitinib [Rinvoq]	0
Ustekinumab [Stelara]	<5

Section 40: personal information

Please note <5 has been added where the number of individuals is 5 or less, this information has been redacted to protect the confidentiality of individuals and to ensure they cannot be identified.